Breaking News

HLI claims that upon his termination in May, Venter took a company-owned laptop and is using HLI trade secrets to build a competing business at JCVI.

The company will work with researchers at UCSD's Moores Cancer Center on two studies of patients with breast, lung, and colon cancers.

As part of the deal, Waters has also placed a Synapt G2-Si mass spec instrument at Purdue University to help advance research applications for DESI.

The final LCD, which expands Medicare coverage of the firm's ConfirmMDx test to all providers, becomes effective on Sept. 3.

The company will supply the Chinese laboratory with its ClearCell FX1 system and help train and assist its new partner in developing cancer tests.

Last week, GenomeWeb's readers were most interested in Foundation Medicine and Guardant Health settling their patent infringement lawsuit.

This drug is the first FDA-approved IDH1 inhibitor and will be used to treat adult patients with relapsed or refractory acute myeloid leukemia.

The researchers said their method for mapping genetic interactions can serve as a blueprint for mapping the genetic landscape of human cells.

One study characterized an allele linked to aggressive prostate cancer, while the other explored the range of structural variations within metastatic disease.

Starting with an 800-year-old sample from Norway, researchers retraced relationships between pig- and human-infecting Salmonella enterica lineages.

Using genome sequencing and phylogenetics, researchers have shown that the industrial yeast Pichia kudriavzevii is genetically the same species as Candida krusei.

The company's Life Sciences segment was up 17 percent year over year, while its Diagnostics business grew 8 percent.

With the new five-year funding, patients across Australia with rare or less common cancers will be able to access the program through a network of eight cancer centers.

IBM's supercomputing platform will continue to provide AI support to advanced cancer patients at VA medical centers for at least another year.

PerkinElmer will offer providers and patients screening for ASAH1 mutations through its PerkinElmer Genomics laboratory unit.

Under the terms of the settlement, the lawsuit, counterclaims, and challenges to the patent in inter partes review have been dismissed.

The company plans to use the funding to build beta units of its optical nanopore sequencer for early adopters in industry and academia.

The firm attributed growth to a diversified geographic footprint and comprehensive offerings based on three key in vitro diagnostics technologies.

The firm booked $484 million in revenues for Alere rapid diagnostics in the quarter, led by sales for infectious disease and cardiometabolic testing.

The company will offer 4 million shares of common stock at a price of $12.50 per share, with an option for underwriters to purchase up to an additional 600,000 shares.

The company, which merged with Transgenomic in 2016, attributed the revenue increase to strong demand for its pathology services.

According to Myriad, a similar deal is in the works with the pharmacy benefit management services provider for its GeneSight pharmacogenetic test.

Pages

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.